Ozempic Revolution In India? Semaglutide Patent Expiry Sparks Generic Rush: Report

As the patent for semaglutide, the active ingredient in the diabetes and weight-loss drug Ozempic, approaches its expiration, Indian pharmaceutical companies are gearing up to introduce more affordable generic alternatives. This development is expected to significantly impact the Indian market, where the rising prevalence of diabetes and obesity has led to an increased demand for effective treatments. The entry of generics will not only provide financial relief to patients but also enhance accessibility to essential medications. With the patent expiry set to open the floodgates for competition, experts believe that this could lead to a price drop, benefiting countless individuals who struggle with the high costs of healthcare. The generics are anticipated to be marketed shortly after the patent lapses, with many companies already in advanced stages of preparation. This situation reflects a broader trend in India, where pharmaceutical firms are increasingly focusing on developing affordable healthcare solutions in response to the growing burden of chronic diseases. The anticipated launch of semaglutide generics aligns with the Indian government's push towards making healthcare more accessible to the masses, thereby transforming the landscape of diabetes management in the country.